IL300090A - Pharmaceutical compositions comprising venglustat - Google Patents
Pharmaceutical compositions comprising venglustatInfo
- Publication number
- IL300090A IL300090A IL300090A IL30009023A IL300090A IL 300090 A IL300090 A IL 300090A IL 300090 A IL300090 A IL 300090A IL 30009023 A IL30009023 A IL 30009023A IL 300090 A IL300090 A IL 300090A
- Authority
- IL
- Israel
- Prior art keywords
- venglustat
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063056075P | 2020-07-24 | 2020-07-24 | |
| EP21152595 | 2021-01-20 | ||
| PCT/IB2021/056673 WO2022018695A1 (en) | 2020-07-24 | 2021-07-23 | Pharmaceutical compositions comprising venglustat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300090A true IL300090A (en) | 2023-03-01 |
Family
ID=77021693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300090A IL300090A (en) | 2020-07-24 | 2021-07-23 | Pharmaceutical compositions comprising venglustat |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11857512B2 (en) |
| EP (1) | EP4185267A1 (en) |
| JP (1) | JP2023534322A (en) |
| KR (1) | KR20230043024A (en) |
| CN (1) | CN116133647A (en) |
| AU (1) | AU2021311131B2 (en) |
| BR (1) | BR112023000798A2 (en) |
| CA (1) | CA3186766A1 (en) |
| CO (1) | CO2023000523A2 (en) |
| IL (1) | IL300090A (en) |
| MX (1) | MX2023001014A (en) |
| TW (1) | TW202220648A (en) |
| WO (1) | WO2022018695A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114040762A (en) | 2019-02-04 | 2022-02-11 | 建新公司 | Treatment of ciliary disease using inhibitors of glucosylceramide synthase (GCS) |
| JP2025541739A (en) | 2022-12-01 | 2025-12-23 | ジェンザイム・コーポレーション | Venglustat in combination with a strong or moderate inhibitor of CYP3A4 |
| WO2025219952A1 (en) | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| WO2025219951A1 (en) | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| WO2025262570A1 (en) | 2024-06-17 | 2025-12-26 | Genzyme Corporation | Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment |
| EP4702971A1 (en) * | 2024-09-03 | 2026-03-04 | Athena Pharmaceutiques SAS | Method for preparation of lisdexamfetamine dimesylate dispersible tablet |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB725228A (en) | 1952-06-19 | 1955-03-02 | Roche Products Ltd | Substituted carbamic acid esters and process for the manufacture thereof |
| BE640616A (en) | 1962-12-19 | |||
| NL130759C (en) | 1965-10-07 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4593034A (en) | 1984-04-06 | 1986-06-03 | A. H. Robins Company, Inc. | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides |
| AU611976B2 (en) | 1987-12-24 | 1991-06-27 | John Wyeth & Brother Limited | Aroyl urea and carbamic acid derivatives of azabicyclo compounds |
| DE3878235T2 (en) | 1988-08-04 | 1993-06-03 | Synthelabo | ANTISCHIZOPHREN EFFECTIVE S-N- (1-AZABICYCLO (2.2.2.) OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES. |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| IT1228293B (en) | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | BENZODERIVATES OF HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN. |
| DK443489D0 (en) | 1989-09-08 | 1989-09-08 | Ferrosan As | SUBSTITUTED URINARY COMPOUNDS, THEIR PREPARATION AND USE |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| GB9106571D0 (en) | 1991-03-27 | 1991-05-15 | Erba Carlo Spa | Derivatives of substituted imidazol-2-one and process for their preparation |
| US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| AU685225B2 (en) | 1994-02-10 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| JPH08198751A (en) | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | Carbamate derivative |
| KR19990067403A (en) | 1995-11-08 | 1999-08-16 | 이곤 이 버그 | 1-aza-bicycloheptane derivatives and their pharmaceutical applications |
| SE9600683D0 (en) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| JP2000515881A (en) | 1996-07-29 | 2000-11-28 | フアーマシア・アンド・アツプジヨン・アー・ベー | Arylcycloalkanecarboxylates, their use, pharmaceutical compositions and preparation |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US6468998B1 (en) | 1998-11-02 | 2002-10-22 | Mitsubishi Pharma Corporation | Pyrrolidine compounds and medicinal utilization thereof |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2791678B1 (en) | 1999-03-30 | 2001-05-04 | Synthelabo | 1,4-DIAZABICYCLO [3.2.2] NONANE-4-CARBOXYLATES AND -CARBOXAMIDES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| KR20020084116A (en) | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-Benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| KR100751981B1 (en) | 2000-06-27 | 2007-08-28 | 라보라토리오스 살바트, 에스.에이. | Carbamate derived from arylalkylamine |
| AU2001284645A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| NZ526580A (en) | 2000-12-22 | 2005-04-29 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| ATE348829T1 (en) | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS FOR TREATING CNS DISORDERS OR OTHER DISEASES |
| JP2003267977A (en) | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | Quinuclidine derivative |
| DE10211415A1 (en) | 2002-03-15 | 2003-09-25 | Bayer Ag | New azabicycloalkyl carboxylic acid N-biarylamides, are alpha-7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance |
| ES2203327B1 (en) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | NEW QUINUCLIDINE CARBAMATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| AU2003246942B2 (en) | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| JPWO2004011430A1 (en) | 2002-07-25 | 2005-11-24 | アステラス製薬株式会社 | Sodium channel inhibitor |
| SE0202430D0 (en) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| JP4750421B2 (en) | 2002-12-06 | 2011-08-17 | ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト | Inhibition of inflammation using α7 receptor binding cholinergic agonists |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| US20050031683A1 (en) * | 2003-08-04 | 2005-02-10 | Ashish Kapoor | Solid pharmaceutical composition |
| TW200529860A (en) | 2003-12-22 | 2005-09-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JP2007186422A (en) | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | Aryl sulfide derivatives |
| JP2008504282A (en) | 2004-06-23 | 2008-02-14 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | Method for treating bowel obstruction by pharmacological activity of cholinergic receptors |
| EP1811991B1 (en) | 2004-11-10 | 2018-11-07 | Genzyme Corporation | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis |
| JP2008545776A (en) | 2005-06-11 | 2008-12-18 | ヴァーナリス アールアンドディー リミテッド | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune diseases |
| CN101312968A (en) | 2005-09-23 | 2008-11-26 | 记忆药物公司 | Indazole, benzothiazole, benzisothiazole, benzisoxazole, pyrazolopyridine, isothiazolopyridine, preparation and use thereof |
| SG131819A1 (en) | 2005-11-07 | 2007-05-28 | Chikka Pte Ltd | Buddy-based cross-carrier messaging system |
| WO2007083978A1 (en) | 2006-01-23 | 2007-07-26 | Crystalgenomics, Inc. | Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same |
| EP1976519A2 (en) | 2006-01-27 | 2008-10-08 | Yale University | Cytisine and acetylcholine analogs and methods of treating mood disorders |
| US7840109B2 (en) | 2006-08-14 | 2010-11-23 | Adc Telecommunications, Inc. | Factory spliced cable assembly |
| EP2119716A4 (en) | 2007-02-09 | 2011-06-01 | Astellas Pharma Inc | Aza-bridged-ring compound |
| MX2009010557A (en) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Method for the treatment of fabry disease using pharmacological chaperones. |
| EP2170065A4 (en) | 2007-06-20 | 2011-11-23 | Merck Sharp & Dohme | DIPHENYL-SUBSTITUTED ALKANES |
| CA2706727A1 (en) | 2007-11-29 | 2009-06-11 | Michael S. Mcgrath | Compositions and methods for treating lysosomal disorders |
| CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| EP2154136A1 (en) | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| WO2010091104A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| WO2010091164A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| WO2010121963A1 (en) | 2009-04-21 | 2010-10-28 | Nerviano Medical Sciences S.R.L. | Resorcinol derivatives as hsp90 inhibitors |
| AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
| EP2959902A1 (en) | 2009-07-23 | 2015-12-30 | Novartis AG | Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia |
| SI3998078T1 (en) | 2009-08-28 | 2026-02-27 | Genzyme Corporation | Enzyme replacement therapy with ascending dose for the treatment of acid sphingomyelinase deficiency |
| US20110183938A1 (en) | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
| ES2709487T3 (en) * | 2010-05-10 | 2019-04-16 | Lesvi Laboratorios Sl | Stable pharmaceutical formulations containing an antihistamine |
| KR101500915B1 (en) | 2010-11-12 | 2015-03-10 | 시오노기세야쿠 가부시키가이샤 | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative, and method for producing the same |
| KR101987736B1 (en) | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | Glucosylceramide synthase inhibitors |
| US20140228575A1 (en) | 2011-06-22 | 2014-08-14 | Isochem | Process for the Preparation of Solifenacin and Salts Thereof |
| CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| US9655946B2 (en) | 2012-09-11 | 2017-05-23 | Hospira Australia Pty Ltd. | Daptomycin formulations and uses thereof |
| MA37975B2 (en) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Glucosylceramide synthase inhibitors |
| MX365464B (en) | 2013-03-15 | 2019-06-04 | Genzyme Corp | Method of preparing glucosylceramide synthase inhibitors. |
| JO3713B1 (en) * | 2013-03-15 | 2021-01-31 | Genzyme Corp | SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate |
| EP3079695B1 (en) | 2013-12-11 | 2021-03-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| TW201642855A (en) * | 2015-03-10 | 2016-12-16 | 健臻公司 | Methods for treating proteinopathies |
| US12472144B2 (en) * | 2017-08-08 | 2025-11-18 | Amneal Pharmaceuticals Llc | Pharmaceutical composition comprising eliglustat |
| CN114040762A (en) | 2019-02-04 | 2022-02-11 | 建新公司 | Treatment of ciliary disease using inhibitors of glucosylceramide synthase (GCS) |
| CN113645969A (en) | 2019-02-04 | 2021-11-12 | 建新公司 | Methods for treating symptoms and disorders associated with lysosomal storage disorders |
| WO2021061701A1 (en) * | 2019-09-25 | 2021-04-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of lucerastat salts and process for preparation thereof |
| JP2023512366A (en) | 2020-02-03 | 2023-03-27 | ジェンザイム・コーポレーション | Methods for treating neurological conditions associated with lysosomal storage diseases |
-
2021
- 2021-07-23 AU AU2021311131A patent/AU2021311131B2/en active Active
- 2021-07-23 CA CA3186766A patent/CA3186766A1/en active Pending
- 2021-07-23 TW TW110127154A patent/TW202220648A/en unknown
- 2021-07-23 IL IL300090A patent/IL300090A/en unknown
- 2021-07-23 MX MX2023001014A patent/MX2023001014A/en unknown
- 2021-07-23 US US17/384,083 patent/US11857512B2/en active Active
- 2021-07-23 JP JP2021564954A patent/JP2023534322A/en active Pending
- 2021-07-23 KR KR1020217038775A patent/KR20230043024A/en active Pending
- 2021-07-23 CN CN202180059425.8A patent/CN116133647A/en active Pending
- 2021-07-23 WO PCT/IB2021/056673 patent/WO2022018695A1/en not_active Ceased
- 2021-07-23 BR BR112023000798A patent/BR112023000798A2/en unknown
- 2021-07-23 EP EP21745451.1A patent/EP4185267A1/en active Pending
-
2023
- 2023-01-17 CO CONC2023/0000523A patent/CO2023000523A2/en unknown
- 2023-11-21 US US18/515,897 patent/US20240091208A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001014A (en) | 2023-03-01 |
| AU2021311131B2 (en) | 2026-02-19 |
| CN116133647A (en) | 2023-05-16 |
| WO2022018695A1 (en) | 2022-01-27 |
| CO2023000523A2 (en) | 2023-01-26 |
| US11857512B2 (en) | 2024-01-02 |
| KR20230043024A (en) | 2023-03-30 |
| CA3186766A1 (en) | 2022-01-27 |
| AU2021311131A1 (en) | 2023-03-23 |
| BR112023000798A2 (en) | 2023-02-07 |
| EP4185267A1 (en) | 2023-05-31 |
| US20220023272A1 (en) | 2022-01-27 |
| TW202220648A (en) | 2022-06-01 |
| JP2023534322A (en) | 2023-08-09 |
| US20240091208A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202019241D0 (en) | Pharmaceutical composition | |
| IL300090A (en) | Pharmaceutical compositions comprising venglustat | |
| IL304290A (en) | Pharmaceutical composition | |
| IL314046A (en) | Ribociclib pharmaceutical compositions | |
| GB202208464D0 (en) | Pharmaceutical composition | |
| GB202019335D0 (en) | Pharmaceutical compositions | |
| GB202104224D0 (en) | Pharmaceutical composition | |
| GB202018068D0 (en) | Pharmaceutical composition | |
| GB202010340D0 (en) | Pharmaceutical composition | |
| GB202102575D0 (en) | Fixed-dose pharmaceutical compositions | |
| IL312071A (en) | Pharmaceutical compositions | |
| GB202013701D0 (en) | Pharmaceutical compositions | |
| IL320961A (en) | Milvexian pharmaceutical compositions | |
| GB202313738D0 (en) | Pharmaceutical compositions | |
| GB202312055D0 (en) | Pharmaceutical compositions | |
| GB202109271D0 (en) | Pharmaceutical composition | |
| GB202108387D0 (en) | Pharmaceutical composition | |
| GB202107518D0 (en) | Pharmaceutical composition | |
| GB202105858D0 (en) | Pharmaceutical composition | |
| GB202105462D0 (en) | Pharmaceutical composition | |
| GB202105049D0 (en) | Pharmaceutical composition | |
| GB202105047D0 (en) | Pharmaceutical composition | |
| GB202005742D0 (en) | Novel pharmaceutical compositions | |
| GB202102095D0 (en) | Pharmaceutical composition | |
| GB202102100D0 (en) | Pharmaceutical composition |